In conclusion, our study uncovered the correlation between circulating autotaxin and cardiac parameters in mice and human patients, and provided solid evidence of the therapeutic application of autotaxin inhibitor in combating obesity‐mediated cardiomyopathy. Here, ENPP2 is linked to cardiomyopathy.